Loading…
Type IV collagen-derived angiogenesis inhibitor: canstatin low expressing in brain-invasive meningiomas using liquid chromatography–mass spectrometry (LC-MS/MS)
Purpose Brain invasion in meningiomas is considered an indicator of more aggressive behavior and worse prognosis. But the precise definition and the prognostic role of brain invasion remains unsolved duo to lacking a standardized workflow of surgical sampling and the histopathological detection. Sea...
Saved in:
Published in: | Journal of neuro-oncology 2023, Vol.161 (2), p.415-423 |
---|---|
Main Authors: | , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c474t-d08c116da554869e968503df49c576bac55922d10ccab4fabc46652ada8018d43 |
---|---|
cites | cdi_FETCH-LOGICAL-c474t-d08c116da554869e968503df49c576bac55922d10ccab4fabc46652ada8018d43 |
container_end_page | 423 |
container_issue | 2 |
container_start_page | 415 |
container_title | Journal of neuro-oncology |
container_volume | 161 |
creator | Pei, Jian Li, Pei Gao, Yun H. Tian, Bao G. Wang, Da Y. Zheng, Yu Liu, Li Y. Zhang, Zhi Y. Huang, Si S. Wen, Min Xu, Xiang Xia, Lei |
description | Purpose
Brain invasion in meningiomas is considered an indicator of more aggressive behavior and worse prognosis. But the precise definition and the prognostic role of brain invasion remains unsolved duo to lacking a standardized workflow of surgical sampling and the histopathological detection. Searching for molecular biomarker expression correlating with brain invasion, could contribute to establish a molecular pathological diagnosis without problems of subjective interobserver variation and deeply understand the mechanism of brain invasion and develop innovative therapeutic strategies.
Methods
We utilized liquid chromatography tandem mass spectrometry to quantify protein abundances between non-invasive meningiomas (n = 21) and brain-invasive meningiomas (n = 21) spanning World Health Organization grades I and III. After proteomic discrepancies were analyzed, the 14 most up-regulated or down-regulated proteins were recorded. Immunohistochemical staining for glial fibrillary acidic protein and most likely brain invasion-related proteins was performed in both groups.
Results
A total of 6498 unique proteins were identified in non-invasive and brain-invasive meningiomas. Canstatin expression in the non-invasive group was 2.1-fold that of the brain-invasive group. The immunohistochemical staining showed canstatin expressed in both groups, and the non-invasive group showed stronger staining for canstatin in the tumor mass (
p
= 0.0132) than the brain-invasive group, which showed moderate intensity.
Conclusion
This study demonstrated the low expression of canstatin in meningiomas with brain invasion, a finding that provide a basis for understanding the mechanism of brain invasion of meningiomas and may contribute to establish molecular pathological diagnosis and identify novel therapeutic targets for personalized care. |
doi_str_mv | 10.1007/s11060-023-04256-z |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9988792</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2783523105</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-d08c116da554869e968503df49c576bac55922d10ccab4fabc46652ada8018d43</originalsourceid><addsrcrecordid>eNp9kstuEzEUhi0EoqHwAiyQJTZlYWqPbzMskFDEpVIqFi2IneWxnYmriT21ZwLpinfgDXg0ngSnKeWyYGXp_N_5fY79A_CY4OcEY3mcCcECI1xRhFnFBbq6A2aES4oklfQumGEiJOIN-3QAHuR8gTFmkpL74ICKmhAp-Ax8P98ODp58hCb2ve5cQNYlv3EW6tD5WAou-wx9WPnWjzG9gEaHPOrRB9jHz9B9GZLL2YeuMLBN2gfkw0bn4gHXLvidy1pnOF0zvb-cvIVmlUpxjF3Sw2r74-u3QmSYB2fGIrgxbeHRYo5Oz45Pz549BPeWus_u0c15CD68eX0-f4cW79-ezF8tkGGSjcji2hAirOac1aJxjag5pnbJGsOlaLXhvKkqS7AxumVL3RomBK-01TUmtWX0ELzc-w5Tu3bWuDAm3ash-bVOWxW1V38rwa9UFzeqaepaNlUxOLoxSPFycnlUa5-NK-8aXJyyqqRsKMeM7tCn_6AXcUqhrFeomvKKEswLVe0pk2LOyS1vhyFY7SKg9hFQJQLqOgLqqjQ9-XON25Zff14AugdykULn0u-7_2P7E9_8wos</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2783523105</pqid></control><display><type>article</type><title>Type IV collagen-derived angiogenesis inhibitor: canstatin low expressing in brain-invasive meningiomas using liquid chromatography–mass spectrometry (LC-MS/MS)</title><source>Springer Nature</source><creator>Pei, Jian ; Li, Pei ; Gao, Yun H. ; Tian, Bao G. ; Wang, Da Y. ; Zheng, Yu ; Liu, Li Y. ; Zhang, Zhi Y. ; Huang, Si S. ; Wen, Min ; Xu, Xiang ; Xia, Lei</creator><creatorcontrib>Pei, Jian ; Li, Pei ; Gao, Yun H. ; Tian, Bao G. ; Wang, Da Y. ; Zheng, Yu ; Liu, Li Y. ; Zhang, Zhi Y. ; Huang, Si S. ; Wen, Min ; Xu, Xiang ; Xia, Lei</creatorcontrib><description>Purpose
Brain invasion in meningiomas is considered an indicator of more aggressive behavior and worse prognosis. But the precise definition and the prognostic role of brain invasion remains unsolved duo to lacking a standardized workflow of surgical sampling and the histopathological detection. Searching for molecular biomarker expression correlating with brain invasion, could contribute to establish a molecular pathological diagnosis without problems of subjective interobserver variation and deeply understand the mechanism of brain invasion and develop innovative therapeutic strategies.
Methods
We utilized liquid chromatography tandem mass spectrometry to quantify protein abundances between non-invasive meningiomas (n = 21) and brain-invasive meningiomas (n = 21) spanning World Health Organization grades I and III. After proteomic discrepancies were analyzed, the 14 most up-regulated or down-regulated proteins were recorded. Immunohistochemical staining for glial fibrillary acidic protein and most likely brain invasion-related proteins was performed in both groups.
Results
A total of 6498 unique proteins were identified in non-invasive and brain-invasive meningiomas. Canstatin expression in the non-invasive group was 2.1-fold that of the brain-invasive group. The immunohistochemical staining showed canstatin expressed in both groups, and the non-invasive group showed stronger staining for canstatin in the tumor mass (
p
= 0.0132) than the brain-invasive group, which showed moderate intensity.
Conclusion
This study demonstrated the low expression of canstatin in meningiomas with brain invasion, a finding that provide a basis for understanding the mechanism of brain invasion of meningiomas and may contribute to establish molecular pathological diagnosis and identify novel therapeutic targets for personalized care.</description><identifier>ISSN: 0167-594X</identifier><identifier>EISSN: 1573-7373</identifier><identifier>DOI: 10.1007/s11060-023-04256-z</identifier><identifier>PMID: 36811765</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Angiogenesis Inhibitors ; Brain - pathology ; Brain cancer ; Chromatography ; Chromatography, Liquid ; Collagen (type IV) ; Collagen Type IV - metabolism ; Diagnosis ; Glial fibrillary acidic protein ; Humans ; Liquid chromatography ; Mass spectrometry ; Mass spectroscopy ; Medical innovations ; Medicine ; Medicine & Public Health ; Meningeal Neoplasms - pathology ; Meningioma - pathology ; Neurology ; Oncology ; Proteins ; Proteomics ; Scientific imaging ; Tandem Mass Spectrometry ; Therapeutic targets</subject><ispartof>Journal of neuro-oncology, 2023, Vol.161 (2), p.415-423</ispartof><rights>The Author(s) 2023</rights><rights>2023. The Author(s).</rights><rights>The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-d08c116da554869e968503df49c576bac55922d10ccab4fabc46652ada8018d43</citedby><cites>FETCH-LOGICAL-c474t-d08c116da554869e968503df49c576bac55922d10ccab4fabc46652ada8018d43</cites><orcidid>0000-0002-7439-7683</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36811765$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pei, Jian</creatorcontrib><creatorcontrib>Li, Pei</creatorcontrib><creatorcontrib>Gao, Yun H.</creatorcontrib><creatorcontrib>Tian, Bao G.</creatorcontrib><creatorcontrib>Wang, Da Y.</creatorcontrib><creatorcontrib>Zheng, Yu</creatorcontrib><creatorcontrib>Liu, Li Y.</creatorcontrib><creatorcontrib>Zhang, Zhi Y.</creatorcontrib><creatorcontrib>Huang, Si S.</creatorcontrib><creatorcontrib>Wen, Min</creatorcontrib><creatorcontrib>Xu, Xiang</creatorcontrib><creatorcontrib>Xia, Lei</creatorcontrib><title>Type IV collagen-derived angiogenesis inhibitor: canstatin low expressing in brain-invasive meningiomas using liquid chromatography–mass spectrometry (LC-MS/MS)</title><title>Journal of neuro-oncology</title><addtitle>J Neurooncol</addtitle><addtitle>J Neurooncol</addtitle><description>Purpose
Brain invasion in meningiomas is considered an indicator of more aggressive behavior and worse prognosis. But the precise definition and the prognostic role of brain invasion remains unsolved duo to lacking a standardized workflow of surgical sampling and the histopathological detection. Searching for molecular biomarker expression correlating with brain invasion, could contribute to establish a molecular pathological diagnosis without problems of subjective interobserver variation and deeply understand the mechanism of brain invasion and develop innovative therapeutic strategies.
Methods
We utilized liquid chromatography tandem mass spectrometry to quantify protein abundances between non-invasive meningiomas (n = 21) and brain-invasive meningiomas (n = 21) spanning World Health Organization grades I and III. After proteomic discrepancies were analyzed, the 14 most up-regulated or down-regulated proteins were recorded. Immunohistochemical staining for glial fibrillary acidic protein and most likely brain invasion-related proteins was performed in both groups.
Results
A total of 6498 unique proteins were identified in non-invasive and brain-invasive meningiomas. Canstatin expression in the non-invasive group was 2.1-fold that of the brain-invasive group. The immunohistochemical staining showed canstatin expressed in both groups, and the non-invasive group showed stronger staining for canstatin in the tumor mass (
p
= 0.0132) than the brain-invasive group, which showed moderate intensity.
Conclusion
This study demonstrated the low expression of canstatin in meningiomas with brain invasion, a finding that provide a basis for understanding the mechanism of brain invasion of meningiomas and may contribute to establish molecular pathological diagnosis and identify novel therapeutic targets for personalized care.</description><subject>Angiogenesis Inhibitors</subject><subject>Brain - pathology</subject><subject>Brain cancer</subject><subject>Chromatography</subject><subject>Chromatography, Liquid</subject><subject>Collagen (type IV)</subject><subject>Collagen Type IV - metabolism</subject><subject>Diagnosis</subject><subject>Glial fibrillary acidic protein</subject><subject>Humans</subject><subject>Liquid chromatography</subject><subject>Mass spectrometry</subject><subject>Mass spectroscopy</subject><subject>Medical innovations</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Meningeal Neoplasms - pathology</subject><subject>Meningioma - pathology</subject><subject>Neurology</subject><subject>Oncology</subject><subject>Proteins</subject><subject>Proteomics</subject><subject>Scientific imaging</subject><subject>Tandem Mass Spectrometry</subject><subject>Therapeutic targets</subject><issn>0167-594X</issn><issn>1573-7373</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kstuEzEUhi0EoqHwAiyQJTZlYWqPbzMskFDEpVIqFi2IneWxnYmriT21ZwLpinfgDXg0ngSnKeWyYGXp_N_5fY79A_CY4OcEY3mcCcECI1xRhFnFBbq6A2aES4oklfQumGEiJOIN-3QAHuR8gTFmkpL74ICKmhAp-Ax8P98ODp58hCb2ve5cQNYlv3EW6tD5WAou-wx9WPnWjzG9gEaHPOrRB9jHz9B9GZLL2YeuMLBN2gfkw0bn4gHXLvidy1pnOF0zvb-cvIVmlUpxjF3Sw2r74-u3QmSYB2fGIrgxbeHRYo5Oz45Pz549BPeWus_u0c15CD68eX0-f4cW79-ezF8tkGGSjcji2hAirOac1aJxjag5pnbJGsOlaLXhvKkqS7AxumVL3RomBK-01TUmtWX0ELzc-w5Tu3bWuDAm3ash-bVOWxW1V38rwa9UFzeqaepaNlUxOLoxSPFycnlUa5-NK-8aXJyyqqRsKMeM7tCn_6AXcUqhrFeomvKKEswLVe0pk2LOyS1vhyFY7SKg9hFQJQLqOgLqqjQ9-XON25Zff14AugdykULn0u-7_2P7E9_8wos</recordid><startdate>2023</startdate><enddate>2023</enddate><creator>Pei, Jian</creator><creator>Li, Pei</creator><creator>Gao, Yun H.</creator><creator>Tian, Bao G.</creator><creator>Wang, Da Y.</creator><creator>Zheng, Yu</creator><creator>Liu, Li Y.</creator><creator>Zhang, Zhi Y.</creator><creator>Huang, Si S.</creator><creator>Wen, Min</creator><creator>Xu, Xiang</creator><creator>Xia, Lei</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-7439-7683</orcidid></search><sort><creationdate>2023</creationdate><title>Type IV collagen-derived angiogenesis inhibitor: canstatin low expressing in brain-invasive meningiomas using liquid chromatography–mass spectrometry (LC-MS/MS)</title><author>Pei, Jian ; Li, Pei ; Gao, Yun H. ; Tian, Bao G. ; Wang, Da Y. ; Zheng, Yu ; Liu, Li Y. ; Zhang, Zhi Y. ; Huang, Si S. ; Wen, Min ; Xu, Xiang ; Xia, Lei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-d08c116da554869e968503df49c576bac55922d10ccab4fabc46652ada8018d43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Angiogenesis Inhibitors</topic><topic>Brain - pathology</topic><topic>Brain cancer</topic><topic>Chromatography</topic><topic>Chromatography, Liquid</topic><topic>Collagen (type IV)</topic><topic>Collagen Type IV - metabolism</topic><topic>Diagnosis</topic><topic>Glial fibrillary acidic protein</topic><topic>Humans</topic><topic>Liquid chromatography</topic><topic>Mass spectrometry</topic><topic>Mass spectroscopy</topic><topic>Medical innovations</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Meningeal Neoplasms - pathology</topic><topic>Meningioma - pathology</topic><topic>Neurology</topic><topic>Oncology</topic><topic>Proteins</topic><topic>Proteomics</topic><topic>Scientific imaging</topic><topic>Tandem Mass Spectrometry</topic><topic>Therapeutic targets</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pei, Jian</creatorcontrib><creatorcontrib>Li, Pei</creatorcontrib><creatorcontrib>Gao, Yun H.</creatorcontrib><creatorcontrib>Tian, Bao G.</creatorcontrib><creatorcontrib>Wang, Da Y.</creatorcontrib><creatorcontrib>Zheng, Yu</creatorcontrib><creatorcontrib>Liu, Li Y.</creatorcontrib><creatorcontrib>Zhang, Zhi Y.</creatorcontrib><creatorcontrib>Huang, Si S.</creatorcontrib><creatorcontrib>Wen, Min</creatorcontrib><creatorcontrib>Xu, Xiang</creatorcontrib><creatorcontrib>Xia, Lei</creatorcontrib><collection>SpringerOpen</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of neuro-oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pei, Jian</au><au>Li, Pei</au><au>Gao, Yun H.</au><au>Tian, Bao G.</au><au>Wang, Da Y.</au><au>Zheng, Yu</au><au>Liu, Li Y.</au><au>Zhang, Zhi Y.</au><au>Huang, Si S.</au><au>Wen, Min</au><au>Xu, Xiang</au><au>Xia, Lei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Type IV collagen-derived angiogenesis inhibitor: canstatin low expressing in brain-invasive meningiomas using liquid chromatography–mass spectrometry (LC-MS/MS)</atitle><jtitle>Journal of neuro-oncology</jtitle><stitle>J Neurooncol</stitle><addtitle>J Neurooncol</addtitle><date>2023</date><risdate>2023</risdate><volume>161</volume><issue>2</issue><spage>415</spage><epage>423</epage><pages>415-423</pages><issn>0167-594X</issn><eissn>1573-7373</eissn><abstract>Purpose
Brain invasion in meningiomas is considered an indicator of more aggressive behavior and worse prognosis. But the precise definition and the prognostic role of brain invasion remains unsolved duo to lacking a standardized workflow of surgical sampling and the histopathological detection. Searching for molecular biomarker expression correlating with brain invasion, could contribute to establish a molecular pathological diagnosis without problems of subjective interobserver variation and deeply understand the mechanism of brain invasion and develop innovative therapeutic strategies.
Methods
We utilized liquid chromatography tandem mass spectrometry to quantify protein abundances between non-invasive meningiomas (n = 21) and brain-invasive meningiomas (n = 21) spanning World Health Organization grades I and III. After proteomic discrepancies were analyzed, the 14 most up-regulated or down-regulated proteins were recorded. Immunohistochemical staining for glial fibrillary acidic protein and most likely brain invasion-related proteins was performed in both groups.
Results
A total of 6498 unique proteins were identified in non-invasive and brain-invasive meningiomas. Canstatin expression in the non-invasive group was 2.1-fold that of the brain-invasive group. The immunohistochemical staining showed canstatin expressed in both groups, and the non-invasive group showed stronger staining for canstatin in the tumor mass (
p
= 0.0132) than the brain-invasive group, which showed moderate intensity.
Conclusion
This study demonstrated the low expression of canstatin in meningiomas with brain invasion, a finding that provide a basis for understanding the mechanism of brain invasion of meningiomas and may contribute to establish molecular pathological diagnosis and identify novel therapeutic targets for personalized care.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>36811765</pmid><doi>10.1007/s11060-023-04256-z</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-7439-7683</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0167-594X |
ispartof | Journal of neuro-oncology, 2023, Vol.161 (2), p.415-423 |
issn | 0167-594X 1573-7373 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9988792 |
source | Springer Nature |
subjects | Angiogenesis Inhibitors Brain - pathology Brain cancer Chromatography Chromatography, Liquid Collagen (type IV) Collagen Type IV - metabolism Diagnosis Glial fibrillary acidic protein Humans Liquid chromatography Mass spectrometry Mass spectroscopy Medical innovations Medicine Medicine & Public Health Meningeal Neoplasms - pathology Meningioma - pathology Neurology Oncology Proteins Proteomics Scientific imaging Tandem Mass Spectrometry Therapeutic targets |
title | Type IV collagen-derived angiogenesis inhibitor: canstatin low expressing in brain-invasive meningiomas using liquid chromatography–mass spectrometry (LC-MS/MS) |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T00%3A37%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Type%20IV%20collagen-derived%20angiogenesis%20inhibitor:%20canstatin%20low%20expressing%20in%20brain-invasive%20meningiomas%20using%20liquid%20chromatography%E2%80%93mass%20spectrometry%20(LC-MS/MS)&rft.jtitle=Journal%20of%20neuro-oncology&rft.au=Pei,%20Jian&rft.date=2023&rft.volume=161&rft.issue=2&rft.spage=415&rft.epage=423&rft.pages=415-423&rft.issn=0167-594X&rft.eissn=1573-7373&rft_id=info:doi/10.1007/s11060-023-04256-z&rft_dat=%3Cproquest_pubme%3E2783523105%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c474t-d08c116da554869e968503df49c576bac55922d10ccab4fabc46652ada8018d43%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2783523105&rft_id=info:pmid/36811765&rfr_iscdi=true |